OptiBiotix Health PLC Change of broker (3118L)

TIDMOPTI

RNS Number : 3118L

OptiBiotix Health PLC

12 January 2021

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

Appointment of Broker

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, a nn o unces the appointment of Cenkos Securities plc as its sole broker with immediate effect.

For further information, please contact:

 
 OptiBiotix Health plc                             www.optibiotix.com 
 Neil Davidson, Chairman                         Contact via Walbrook 
                                                                below 
 Stephen O'Hara, Chief Executive 
 
 Cairn Financial Advisers LLP (NOMAD)              Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                    Tel: [phone] 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                   Mob: [phone] 
 Anna Dunphy 
 
 
   About OptiBiotix   -  www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPSFAFWFEFSEIF

(END) Dow Jones Newswires

January 12, 2021 02:00 ET (07:00 GMT)